Retesting Thymosin Alpha-1: following up on last cycle's discrepancies
Purity across our Thymosin Alpha-1 samples ranged from 98% to 99.2%. Here is the context.
The Peptide Institute Testing Desk··Updated ·11 min read
Thymosin Alpha-1 is an immunomodulatory thymic peptide with a development status of "approved in several countries". The Institute rates the strength of its published evidence as moderate. A thymic peptide used clinically in parts of Asia and Europe as an immune modulator, particularly alongside hepatitis treatment.
This report covers the Thymosin Alpha-1 samples processed in our most recent testing cycle. Every specimen was purchased anonymously at retail, transferred under chain-of-custody documentation, and analysed by an independent contract laboratory.
The Institute has independently tested 2 Thymosin Alpha-1 samples from 2 companies. 100% met their label claims on purity and content. Measured purity ranged from 98% to 99.2%, averaging 98.6%. Every specimen is published in full, including the laboratory that ran it.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
224 independent tests across 20 companies and 55 compounds. The industry is bifurcating, and the gap is measurable.
Institute Investigation
Free download
Get the free Peptide Playbook, plus new breakthroughs as they happen.
What peptides are, why people are using them, and what results people are talking about,
in plain English. Sign up and we email you the Playbook right away.
